Analyst firms · Oppenheimer · EXEL
Oppenheimer EXEL price target and rating history
Exelixis Inc. (EXEL) · Health Care
Oppenheimer rates Exelixis Inc. (EXEL) Perform with a $29 price target, as of its latest action on Jan 24, 2025. It has published 3 rating actions on EXEL since November 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a EXEL price target in the last 12 months, the median target is $52.
- Current rating
- Perform
- Price target
- $29
- Median target, all firms
- $52
- Actions on EXEL
- 3
Oppenheimer price target on EXEL
Every Oppenheimer rating on EXEL
- Jan 24, 2025
- Aug 22, 2023
- Nov 2, 2021
How other firms rate EXEL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BMO Capital Markets | Market Perform | $54 | Aug 19, 2026 |
| Leerink Partners | Market Perform | $52 | Aug 6, 2026 |
| Truist Securities | Hold | $54 | Jun 25, 2026 |
| Morgan Stanley | Equal-Weight | $48 | Jan 8, 2026 |
| BofA Securities | Underperform | $41 | Jan 5, 2026 |
| Wolfe Research | Peer Perform | Nov 18, 2025 |
Questions about Oppenheimer and EXEL
- What is Oppenheimer's price target for EXEL?
- Oppenheimer's latest stated price target for Exelixis Inc. (EXEL) is $29, from its action on Aug 22, 2023.
- What is Oppenheimer's rating on EXEL?
- Oppenheimer rates EXEL Perform, a neutral rating, as of Jan 24, 2025.
- When did Oppenheimer last change its view on EXEL?
- On Jan 24, 2025, Oppenheimer downgrades to Perform from Outperform.
- How does Oppenheimer's EXEL target compare with other analysts?
- Across 5 firms with a EXEL price target in the last 12 months, the median target is $52.
More EXEL rating histories
All Oppenheimer ratingsEXEL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.